REGISTER HERE.

Our goal is to join community-based providers and academic oncologists to improve the care and outcomes of patients with hematologic malignancies. In order to reach this goal, the Annual Updates from ASH 2020: Practice Changing Abstracts addresses early treatment options and medical advances that can be implemented in an effort to reduce cancer-related deaths. Our overarching goal is to help all healthcare professionals who are involved in the care of patients with hematologic malignancies to stay on top of the latest scientific updates, innovative ideas, and timeliest issues related to their care. The aim of the conference is to provide the target audience with information that can help improve your patient management and care strategies.  

This meeting provides the opportunity to hear and discuss with our expert faculty rapidly evolving developments, discover new treatments for patients, and improve overall practice paradigms. We want to educate and empower community-based oncologists on best practices for treating hematologic cancers and also inform them of the indicators of when a patient needs to be referred for tertiary level care.

TARGET AUDIENCE

This activity is designed for physicians and other healthcare professionals dedicated to the treatment of hematologic cancers.

EDUCATIONAL OBJECTIVES

At the conclusion of this activity, participants will be able to:

• Illustrate how cutting-edge data presented at the 2020 Annual Meeting of the American Society of Hematology (ASH) can apply to clinical practice, addressing best practices and guidelines;
• State the emerging treatment strategies for patients with low-risk and high-risk myeloid malignancies;
• Discuss the optimal patient selection, timing, and regimen for transplant;
• Evaluate clinical trial data in the context of CAR T-cell therapy and its place in evolving hematologic malignancy treatment standards;
• Choose the optimal treatment, sequencing, and supportive care strategies for patients with lymphoma using evidence-based guidelines;
• Identify methods for integrating therapeutic advances into practice to improve current myeloma patient care;
• Describe the pathogenesis, diagnostic evaluation and therapeutic modalities available for common benign hematologic diseases.

ACCREDITATION

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

For more information please visit the official event page.